Pernix Therapeutics to Report Third Quarter 2013 Financial Results on November 12, 2013

  Pernix Therapeutics to Report Third Quarter 2013 Financial Results on
  November 12, 2013

  Management to Host a Conference Call on November 12, 2013 at 9:00 a.m. EDT

Business Wire

HOUSTON -- October 24, 2013

Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical
company, today announced that it will release its third quarter 2013 financial
results before the U.S. stock market opens on Tuesday, November 12, 2013 and
has scheduled a conference call at 9:00 a.m. EDT that day to discuss the
financial results.

The conference call will feature remarks by Michael Pearce, Chairman of the
Board, President, and Chief Executive Officer, and Tracy Clifford, Principal
Accounting Officer. To participate in the conference call, please dial (877)
312-8783 (domestic) or (408) 940-3874 (international). Participants can
reference the passcode 75172136. Please dial in approximately 5 minutes prior
to the call.

The conference call will also be available via a live listen-only webcast and
can be accessed through the Investor Relations section of the Company’s
website www.pernixtx.com. The passcode is 75172136. Please allow extra time
prior to the call to visit the Company’s website and download any software
that may be needed to listen to the webcast.

A replay of the conference call will be available through November 19, 2013,
at (855) 859-2056 domestic and (404) 537-3406 international. The passcode for
the replay is 75172136. An online archive of the webcast will be available on
the Company’s website for 30 days following the call.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on
the sales, marketing, manufacturing and development of branded, generic and
OTC pharmaceutical products. The Company’s branded products for the pediatrics
market include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a
topical treatment for head lice marketed under a co-promotion agreement with
ParaPRO, LLC, and a family of treatments for cough and cold (ZUTRIPRO®,
BROVEX®, ALDEX® and PEDIATEX®). The Company’s branded products for
gastroenterology include OMECLAMOX-PAK®, a 10-day treatment for H. pylori
infection and duodenal ulcer disease, and REZYST™, a probiotic blend to
promote dietary management. The Company also markets the branded product,
SILENOR®, for the treatment of insomnia. The Company promotes its branded
pediatric and gastroenterology products through its sales force. Pernix
markets its generic products through its wholly-owned subsidiaries, Cypress
Pharmaceutical and Macoven Pharmaceuticals. The Company’s wholly-owned
subsidiary, Pernix Manufacturing, manufactures and packages products for the
pharmaceutical industry in a wide range of dosage-forms.

Additional information about Pernix is available on the Company’s website
located at www.pernixtx.com.

Contact:

Pernix Therapeutics Holdings, Inc.
Michael C. Pearce, 843-654-7720 Ext. 7407
President and CEO
mpearce@pernixtx.com
 
Press spacebar to pause and continue. Press esc to stop.